A phase II clinical and pharmacodynamic study of e7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: Modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor

被引:57
作者
Haddad, RI
Weinstein, LJ
Wieczorek, TJ
Bhattacharya, N
Raftopoulos, H
Oster, MW
Zhang, XX
Latham, VM
Costello, R
Faucher, J
DeRosa, C
Yule, M
Miller, LP
Loda, M
Posner, MR
Shapiro, GI
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[4] Columbia Univ, Dept Med, Div Med Oncol, New York Presbyterian Hosp, New York, NY USA
[5] Eisai Med Res Inc, Teaneck, NJ USA
[6] Eisai Med Res Inc, London, England
关键词
D O I
10.1158/1078-0432.CCR-04-0229
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: E7070 is a synthetic sulfonamide cell cycle inhibitor that induces hypophosphorylation of the retinoblastoma (Rb) protein and G(1) arrest in vitro. This Phase II study was conducted to explore the efficacy, safety, and pharmacodynamics of E7070 in squamous cell carcinoma of the head and neck (SCCHN). Experimental Design: Patients with metastatic, recurrent, or refractory SCCHN, treated with no more than one prior therapy for recurrent disease, received E7070 at 700 mg/m(2) over 1 h every 3 weeks. Pre- and posttreatment tumor fine needle aspirates were subjected to inummohistochemistry with a panel of phospho-specific anti-Rb antibodies. End points included progression-free survival, response rate and duration, overall survival, toxicity profile, and inhibition of Rb phosphorylation. Results: Because none of the first 15 patients achieved progression-free survival > 4 months, the early stopping rule was invoked. Eleven patients had oropharyngeal cancer and 12 were male. Median age was 59 years (range, 49-73 years). Thirty-nine cycles of E7070 were delivered (median, 2.6 cycles/patient; range, 1-5 cycles). Six patients had stable disease after 2 cycles and 2 patients each subsequently received 1, 2, and 3 additional cycles, respectively, before experiencing progression. Immunohistochemistry of tumor cell aspirates from 3 patients demonstrated reduced Rb phosphorylation posttreatment. Conclusions: At this dose and schedule, E7070 is unlikely to be superior over single-agent chemotherapy in SCCHN. However, the data suggest that cdk activity can be inhibited in tumor cells, resulting in posttreatment modulation of Rb phosphorylation. In the absence of cytotoxicity, more frequent administration of E7070 may be required to sustain Rb hypophosphorylation and cytostatic growth arrest.
引用
收藏
页码:4680 / 4687
页数:8
相关论文
共 45 条
[1]
Systemic chemotherapy for squamous cell head and neck cancer [J].
Adelstein, DJ .
EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (12) :2151-2163
[2]
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists [J].
Chen, YNP ;
Sharma, SK ;
Ramsey, TM ;
Jiang, L ;
Martin, MS ;
Baker, K ;
Adams, PD ;
Bair, KW ;
Kaelin, WG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4325-4329
[3]
Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation [J].
ConnellCrowley, L ;
Harper, JW ;
Goodrich, DW .
MOLECULAR BIOLOGY OF THE CELL, 1997, 8 (02) :287-301
[4]
Dittrich C, 2003, CLIN CANCER RES, V9, P5195
[5]
Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells [J].
Fukuoka, K ;
Usuda, J ;
Iwamoto, Y ;
Fukumoto, H ;
Nakamura, T ;
Yoneda, T ;
Narita, N ;
Saijo, N ;
Nishio, K .
INVESTIGATIONAL NEW DRUGS, 2001, 19 (03) :219-227
[6]
GERDES J, 1984, J IMMUNOL, V133, P1710
[7]
Haddad Robert I, 2003, Expert Rev Anticancer Ther, V3, P331, DOI 10.1586/14737140.3.3.331
[8]
A PHASE-III RANDOMIZED STUDY COMPARING CISPLATIN AND FLUOROURACIL AS SINGLE AGENTS AND IN COMBINATION FOR ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].
JACOBS, C ;
LYMAN, G ;
VELEZGARCIA, E ;
SRIDHAR, KS ;
KNIGHT, W ;
HOCHSTER, H ;
GOODNOUGH, LT ;
MORTIMER, JE ;
EINHORN, LH ;
SCHACTER, L ;
CHERNG, N ;
DALTON, T ;
BURROUGHS, J ;
ROZENCWEIG, M .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (02) :257-263
[9]
Cancer statistics, 2003 [J].
Jemal, A ;
Murray, T ;
Samuels, A ;
Ghafoor, A ;
Ward, E ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (01) :5-26
[10]
Jiang J, 2003, CANCER RES, V63, P7410